Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05728359 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Genomic Determinants of Outcome in Cardiogenic Shock

Study acronym: Goldilocs
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Nov 1, 2025 to Nov 1, 2026
    • Study completion date: Nov 1, 2025 to Dec 31, 2026
    v3
  2. Primary and study completion dates: Jul 1, 2025 to Nov 1, 2025
    • Start date: Sep 20, 2022 to Aug 8, 2022
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this project is to understand the heterogeneity of both the immune consequences and treatment responses in CS. We will explore this heterogeneity through identification of transcriptomic sub-phenotypes and their association with outcomes, including therapeutic responses.
Trial Details
NCT Number NCT05728359
Lead Sponsor Barts & The London NHS Trust
Collaborators: University of Oxford
Conditions
(from sponsor)		 Cardiogenic Shock
Related terms Shock, Cardiogenic
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov